Higher co-payments reduce use of antidepressants

As they struggle to contain skyrocketing medication costs, health plans across the U.S. have responded by implementing multi-tiered formularies requiring higher copayments for 'non-preferred' medications. New research from Brandeis University published in the Journal of Mental Health Policy and Economics suggests that the prevalent multi-tiered formulary system does impact how patients fill anti-depressant prescriptions, even though antidepressants have certain characteristics that can make it difficult for patients to switch medications.

The study evaluated claims and eligibility files for a large nonprofit managed care organization that started introducing its three-tier formulary in 2000. The sample included 109,686 individuals. The study included a comparison group in the same health plan, consisting of members who did not yet have a three-tier formulary. Under the new formulary, certain brand drugs were classified as 'non-preferred' and started costing the patient $25 per prescription instead of $10.

"The patterns of use do change after a three-tier formulary is implemented," said co-author Dominic Hodgkin, a researcher at the Institute for Behavioral Health, the Heller School for Social Policy and Management at Brandeis University. In the study, for the antidepressants that became non-preferred, prescriptions per plan member decreased 11 percent in the three-tier group, and increased 5 percent in the comparison group.

The study found that out-of-pocket spending increased while the health plan's spending per user decreased. Notably, the proportion of plan members using antidepressants decreased, unlike what previous studies have found for other classes of drugs, such as medications for high cholesterol and heart disease, when they faced similar price incentives.

Hodgkin and his colleagues wanted to learn how this dominant approach—by 2003, 78 percent of health plans had adopted multi-tiered formularies—was affecting treatment of depression. Antidepressants are an important class to study for several reasons, the study notes. First, both patients and physicians are believed to be less willing to switch medications.

Second, many patients stop taking antidepressants within three months of beginning treatment. Third, many patients take antidepressants to treat conditions such as insomnia and migraine. The decision to take antidepressants is complex itself, in part because of the nature of depression.

Hodgkin said that continued monitoring of how three-tier formularies affect care is needed.

Source: Brandeis University

Related stories:

Scientists learn how food affects the brain
In addition to helping protect us from heart disease and cancer, a balanced diet and regular exercise can also protect the brain and ward off mental disorders.
Depression after stroke: A neglected problem
People who have had a stroke and the people who are close to them need more support in order to manage the consequences of stroke. As well as the physical disabilities, the psychological burden is difficult to cope with. It is not only stroke patients who become depressed: their friends and relatives often become depressed too.
Falls, depression and antidepressants in later life
Older people are at high risk for falls and subsequent injuries. Those who have depression have an increased risk of falls and the medications they take for depression increase their risk even more, New Zealand and Australian researchers reported in the open-access journal PLoS ONE.
Antidepressants do work in depression while evidence for CBT is poorer say experts
A new revision of clinical guidelines to help doctors manage patients with depression has challenged the rationale behind the UK government’s policy of rolling out of cognitive behavioural therapy (CBT) for milder depression.
Children with ADHD should get heart tests before treatment with stimulant drugs
Children with attention deficit hyperactivity disorder (ADHD) should get careful cardiac evaluation and monitoring – including an electrocardiogram (ECG) – before treatment with stimulant drugs, a new American Heart Association statement recommends.
Marketing of unproven genetic tests a threat to public health
No mechanism currently exists to ensure that genetic tests are supported by adequate evidence before they go to market, or that marketing claims are truthful and not misleading, according to a policy analysis to be published April 4 in Science. Misleading claims about genetic tests may lead health-care providers and patients to make inappropriate decisions about which tests to take and how to use genetic tests that have potential for profound medical consequences, the authors argue.
A link between antidepressants and type 2 diabetes
While analyzing data from Saskatchewan health databases, Lauren Brown, researcher with the U of A’s School of Public Health, found people with a history of depression had a 30 per cent increased risk of type 2 Diabetes.
Prescription costs rise more than 6 times when patients reach 65 says study of 5M people
Prescribing costs increase dramatically when people reach 65, according to a detailed analysis of more than five million patients published in the March issue of the British Journal of Clinical Pharmacology.

News discussion:

Medicine & Health news